Request Demo
Last update 07 Mar 2025
Antengene Corporation Co., Ltd.
Last update 07 Mar 2025
Overview
Tags
Neoplasms
Hemic and Lymphatic Diseases
Immune System Diseases
Bispecific T-cell Engager (BiTE)
Small molecule drug
Radiolabeled antibody
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTR20211144
一项在晚期实体瘤或非霍奇金淋巴瘤受试者中评价 ATG-019（单药或联合烟酸）安全性和耐受性的I期开放性研究
[Translation] A Phase I open-label study evaluating the safety and tolerability of ATG-019 (alone or in combination with niacin) in subjects with advanced solid tumors or non-Hodgkin lymphoma
CTR20211496
一项在晚期实体肿瘤受试者中评估ATG-016单药安全性、药代动力学和初步疗效的Ib/II期开放性、多中心、剂量探索研究
[Translation] A Phase Ib/II open-label, multicenter, dose-finding study evaluating the safety, pharmacokinetics, and preliminary efficacy of ATG-016 monotherapy in subjects with advanced solid tumors
CTR20201615
一项ATG-008用于治疗NFE2L2、STK11、RICTOR或其他特异性基因变异的晚期实体肿瘤患者的单臂、开放、篮式、II期临床研究
[Translation] A single-arm, open-label, basket-type, Phase II clinical study of ATG-008 in patients with advanced solid tumors harboring NFE2L2, STK11, RICTOR or other specific gene mutations
100 Clinical Results associated with Antengene Corporation Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Antengene Corporation Co., Ltd.
Login to view more data
100 Translational Medicine associated with Antengene Corporation Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 28 Mar 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
9
1
IND Approval
Approved
1
3
Other
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free